KR20020012221A - 체액성 및 세포성 면역 반응을 증진시키기 위한, 안정성과생체 적합성이 최적화된 애쥬반트 - Google Patents

체액성 및 세포성 면역 반응을 증진시키기 위한, 안정성과생체 적합성이 최적화된 애쥬반트 Download PDF

Info

Publication number
KR20020012221A
KR20020012221A KR1020017014653A KR20017014653A KR20020012221A KR 20020012221 A KR20020012221 A KR 20020012221A KR 1020017014653 A KR1020017014653 A KR 1020017014653A KR 20017014653 A KR20017014653 A KR 20017014653A KR 20020012221 A KR20020012221 A KR 20020012221A
Authority
KR
South Korea
Prior art keywords
sba
lipid
adjuvant
particles
oil
Prior art date
Application number
KR1020017014653A
Other languages
English (en)
Korean (ko)
Inventor
레이너 헬무트 뮐러
니콜라스 그루호퍼
카스텐 올브리치
Original Assignee
파르마솔 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파르마솔 게엠베하 filed Critical 파르마솔 게엠베하
Publication of KR20020012221A publication Critical patent/KR20020012221A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
KR1020017014653A 1999-05-20 2000-05-19 체액성 및 세포성 면역 반응을 증진시키기 위한, 안정성과생체 적합성이 최적화된 애쥬반트 KR20020012221A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19923256.3 1999-05-20
DE19923256 1999-05-20
PCT/EP2000/004565 WO2000071154A2 (de) 1999-05-20 2000-05-19 Stabilitäts-, biokompatibilitäts-optimiertes adjuvans (sba) zur erhöhung der humoralen und zellulären immunantwort

Publications (1)

Publication Number Publication Date
KR20020012221A true KR20020012221A (ko) 2002-02-15

Family

ID=7908697

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017014653A KR20020012221A (ko) 1999-05-20 2000-05-19 체액성 및 세포성 면역 반응을 증진시키기 위한, 안정성과생체 적합성이 최적화된 애쥬반트

Country Status (11)

Country Link
EP (1) EP1183045A2 (ja)
JP (1) JP2003500365A (ja)
KR (1) KR20020012221A (ja)
AU (2) AU5214200A (ja)
BR (1) BR0010823A (ja)
CA (1) CA2373239A1 (ja)
DE (1) DE10024788A1 (ja)
MX (1) MXPA01011660A (ja)
TR (1) TR200103333T2 (ja)
WO (2) WO2000071154A2 (ja)
ZA (1) ZA200109147B (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140026638A (ko) * 2005-09-14 2014-03-05 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5214200A (en) * 1999-05-20 2000-12-12 Pharmasol Gmbh Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ES2425392T3 (es) 2002-03-20 2013-10-15 Mannkind Corporation Cartucho para un aparato de inhalación
JP2007509164A (ja) * 2003-10-23 2007-04-12 カイロン コーポレイション 安定化組成物
FR2873386B1 (fr) 2004-07-22 2011-01-14 Agence Francaise De Securite Sanitaire Des Aliments Afssa Composition vaccinale contre le rhodococcus equi
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
PL1791542T3 (pl) 2004-08-23 2015-11-30 Mannkind Corp Sole diketopiperazyny do dostarczania leków
EP2497484A3 (en) 2006-02-22 2012-11-07 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
DK2570147T3 (da) 2008-06-13 2018-01-29 Mannkind Corp Tørpulverinhalator og system til lægemiddelindgivelse
KR101628410B1 (ko) 2008-06-20 2016-06-08 맨카인드 코포레이션 흡입 활동에 관한 실시간 프로파일링을 위한 대화형 장치 및 방법
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US8734845B2 (en) 2009-06-12 2014-05-27 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
MY180552A (en) 2011-04-01 2020-12-02 Mannkind Corp Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
WO2013063160A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
EP2844195B1 (en) 2012-04-30 2019-03-20 Össur HF Prosthetic device, system and method for increasing vacuum attachment
CA2878457C (en) 2012-07-12 2021-01-19 Mannkind Corporation Dry powder drug delivery systems and methods
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
BR112015023168B1 (pt) 2013-03-15 2021-08-10 Mannkind Corporation Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
CN114848614A (zh) 2013-07-18 2022-08-05 曼金德公司 热稳定性干粉药物组合物和方法
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
EP3386540A1 (en) * 2015-12-08 2018-10-17 GlaxoSmithKline Biologicals S.A. Novel adjuvant formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19745950A1 (de) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation
EP1100464A1 (en) * 1998-07-31 2001-05-23 Korea Institute Of Science And Technology Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier
AU5214200A (en) * 1999-05-20 2000-12-12 Pharmasol Gmbh Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140026638A (ko) * 2005-09-14 2014-03-05 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법

Also Published As

Publication number Publication date
ZA200109147B (en) 2002-05-08
TR200103333T2 (tr) 2002-04-22
CA2373239A1 (en) 2000-11-30
BR0010823A (pt) 2002-03-05
AU5809100A (en) 2000-12-12
DE10024788A1 (de) 2000-11-23
WO2000071154A2 (de) 2000-11-30
AU5214200A (en) 2000-12-12
MXPA01011660A (es) 2004-04-05
WO2000071154A3 (de) 2001-06-28
EP1183045A2 (de) 2002-03-06
WO2000071077A2 (en) 2000-11-30
JP2003500365A (ja) 2003-01-07

Similar Documents

Publication Publication Date Title
KR20020012221A (ko) 체액성 및 세포성 면역 반응을 증진시키기 위한, 안정성과생체 적합성이 최적화된 애쥬반트
JP6625587B2 (ja) Ｔｌｒ２を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用
Mohammed et al. Lyophilisation and sterilisation of liposomal vaccines to produce stable and sterile products
Christensen et al. Liposome-based cationic adjuvant formulations (CAF): past, present, and future
ES2258108T3 (es) Vacunas con respuesta inmune mejorada y procedimientos de preparacion de las mismas.
US8277823B2 (en) Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
EP1765289B1 (en) Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
Liu et al. Cubosome nanoparticles potentiate immune properties of immunostimulants
JP2014528955A5 (ja)
AU2008307042B2 (en) Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
KR100726818B1 (ko) 오일 면역 보강제 백신
ES2924988T3 (es) Composiciones con nanoemulsiones para prevenir, inhibir o eliminar una enfermedad alérgica e inflamatoria
Bobbala et al. Novel injectable pentablock copolymer based thermoresponsive hydrogels for sustained release vaccines
JPH06504759A (ja) リポソーム含有ワクチン組成物
US20200405846A1 (en) Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration
Perrie et al. Recent developments in particulate-based vaccines
US20100209452A1 (en) Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
ES2234152T3 (es) Vectores de antigenos en forma de vesiculas multilamelares.
US20220257753A1 (en) Vaccine Adjuvants for Antigen Delivery
Patel et al. Cationic nanoparticles for delivery of CpG oligodeoxynucleotide and ovalbumin: In vitro and in vivo assessment
Kirby Formulation and characterisation of an effective particulate delivery vehicle for the novel sub-unit vaccine antigen, Ag85B-ESAT-6
Christensen et al. Liposomes in adjuvant systems for parenteral delivery of vaccines
Hoseinjani et al. Evaluation of infection course in mice induced by L. major in presence of positively charged liposomes containing CpG ODN
Demana ISCOMs and related colloidal particles prepared by the lipid film hydration method for antigen delivery

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid